摘要
目的：探讨阿立哌唑与氯氮平对首发精神分裂症患者的临床疗效及安全性。方法：对64例精神分裂症患者随机分为两组，分别给予阿立哌唑与氯氮平治疗，疗程8周。用阳性与阴性症状量表（PANSS）和副反应量表（TESS）评定疗效和不良反应。结果：两组疗效差异无显著性（P〉0．05），阿立哌唑不良反应显著少于氯氮平（P〈0.01）。结论：阿立哌唑是一种安全有效的抗精神病药。
Objective：To detect the clinical efficacy and side effect of aripiprazole and clozapine in the treatment of first episode schizophrenic patients. Method：64 schizophrenic inpatients have been divided into aripiprazole group and clozapine group randomly to treat for 8 weeks. Positive and negative symptom scale（PANSS） and treatment emergent symptom scale（TESS） were used to evaluate the efficacy and side effects respectively. Results：There were no significant difference in efficacy between two groups. Aripiprazole had less side effects than clozapine. Conclusion：Aripiprazole is a safe and effective antipsychotic drug.
出处
《临床精神医学杂志》
CAS
2006年第1期44-45,共2页
Journal of Clinical Psychiatry
